Published in Lab Law Weekly, March 2nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Abbott.
Report 1: Abbott (ABT) and Kos Pharmaceuticals, Inc. (KOSP) announced a definitive agreement for Abbott to acquire Kos for $78 per share in cash, for a total transaction value of $3.7 billion, net of cash currently held by Kos.
Based in Cranbury, New Jersey, Kos is a specialty pharmaceutical company that develops and markets proprietary medications for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company has a growing presence in the $20...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly